Outpatient Management Of TTP
Outpatient Follow Up
VISITS AND STANDARD LABS
After discharge, we recommend weekly clinical evaluations and lab visits for a month or while tapering steroids. Routine labs for monitoring include CBC with differential, comprehensive metabolic panel, reticulocyte count, and LDH. Afterward clinic and lab visits should be conducted monthly for 5 months followed by every 3 months thereafter.
ADAMTS-13 activity testing
If the patient is on Caplacizumab, (1-2) The USTMA recommends checking ADAMTS-13 activity weekly.
If the ADAMTS-13 has increased > 10% in 2 consecutive weeks or > 30% in one occasion then, Caplacizumab can be discontinued. We suggest checking ADAMTS-13 activity weekly for 1-month followed by monthly for 3 months and then every 3 months subsequently.
Outpatient Follow Up (Cont)
If the ADAMTS-13 remains < 10% after completion of 28 days of Caplacizumab, USTMA suggests considering extending Caplacizumab for an additional 4 weeks and intensifying immunosuppression with Rituximab(3), if not already given, or with cyclosporine, cyclophosphamide, bortezomib, vincristine or mycophenolate.
The choice of immunosuppressive therapy is based upon several factors, including the patient’s age, other comorbidities (including renal failure), drug access, and the physician’s comfort level and experience.
ADAMTS-13 activity should be checked weekly for a month, monthly for 3 months, and then every 3-month interval thereafter.
Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016; 374:511-522
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019; 380:335-346
McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA.Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010 Jun; 8(6):1201-8.
Jestin M, Benhamou Y, Schelpe AS, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132:2143-2153